Search results for "Epidermal growth factor"

showing 7 items of 227 documents

EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells.

2015

KRAS mutational status is considered a negative predictive marker of the response to anti-EGFR therapies in colorectal cancer (CRC) patients. However, conflicting data exist regarding the variable response to EGFR-targeted therapy. The effects of oncogenic KRAS on downstream targets were studied in cell lines with different KRAS mutations. Cells harboring a single KRASG13D allele showed the most tumorigenic profile, with constitutive activation of the downstream pathway, rendering them EGF-unresponsive. Conversely, KRASA146T cells showed a full EGF-response in terms of signal transduction pathways, cell proliferation, migration or adhesion. Moreover, the global acetylome of CRC cells was al…

lcsh:MedicineBiologymedicine.disease_causeHeterogeneous-Nuclear RibonucleoproteinsProto-Oncogene Proteins p21(ras)Epidermal growth factorCell Line TumormedicineHumansCell adhesionlcsh:ScienceMutationMultidisciplinaryEpidermal Growth FactorCell growthlcsh:RAcetylationCell migrationHCT116 CellsGene Expression Regulation NeoplasticDrug Resistance NeoplasmAcetylationMutationCancer researchlcsh:QKRASSignal transductionColorectal NeoplasmsResearch ArticleSignal TransductionPLoS ONE
researchProduct

Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs

2016

Tyrosine kinase inhibitors (TKIs), which have revolutionized cancer therapy over the past 15 years, are limited in their clinical application due to serious side effects. Therefore, we converted two approved TKIs (sunitinib and erlotinib) into 2-nitroimidazole-based hypoxia-activatable prodrugs. Kinetics studies showed very different stabilities over 24 h; however, fast reductive activation via E. coli nitroreductase could be confirmed for both panels. The anticancer activity and signaling inhibition of the compounds against various human cancer cell lines were evaluated in cell culture. These data, together with molecular docking simulations, revealed distinct differences in the impact of …

medicine.drug_classPharmacology010402 general chemistry01 natural sciencesBiochemistryArticleTyrosine-kinase inhibitor03 medical and health sciencesNitroreductase0302 clinical medicinetyrosine kinase inhibitorsDrug DiscoverymedicinecancerEpidermal growth factor receptorGeneral Pharmacology Toxicology and PharmaceuticsPharmacologybiologyhypoxiaSunitinibChemistryOrganic ChemistryProdrugtargeted therapeutic0104 chemical sciencesSettore CHIM/03 - Chimica Generale E InorganicaCell culture030220 oncology & carcinogenesisbiology.proteinMolecular MedicineErlotinibprodrugTyrosine kinasemedicine.drugChemMedChem
researchProduct

The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis.

2007

Endocannabinoids are lipid signaling mediators that exert an important neuromodulatory role and confer neuroprotection in several types of brain injury. Excitotoxicity and stroke can induce neural progenitor (NP) proliferation and differentiation as an attempt of neuroregeneration after damage. Here we investigated the mechanism of hippocampal progenitor cell engagement upon excitotoxicity induced by kainic acid administration and the putative involvement of the CB1 cannabinoid receptor in this process. Adult NPs express kainate receptors that mediate proliferation and neurosphere generation in vitro via CB1 cannabinoid receptors. Similarly, in vivo studies showed that excitotoxicity-induce…

medicine.medical_specialtyKainic acidCannabinoid receptorNeurotoxinsExcitotoxicityKainate receptorBiologymedicine.disease_causeBiochemistryNeuroprotectionHippocampuschemistry.chemical_compoundMiceReceptor Cannabinoid CB1Epidermal growth factorInternal medicinemedicineAnimalsMolecular BiologyCell ProliferationMice KnockoutNeuronsKainic AcidStem CellsNeurogenesisCell BiologyEndocannabinoid systemCell biologyNerve RegenerationEndocrinologynervous systemchemistrylipids (amino acids peptides and proteins)Fibroblast Growth Factor 2The Journal of biological chemistry
researchProduct

Expression of differentiation antigens and growth-related genes in normal kidney, autosomal dominant polycystic kidney disease, and renal cell carcin…

1992

Cellular differentiation and mRNA levels of genes involved in kidney growth were investigated in normal kidney cells, cyst-lining epithelial cells of polycystic kidney disease, and renal carcinoma cells (RCC). All cells comparatively studied exhibited an antigenic phenotype of proximal tubular cells as shown by the expression of a panel of brush border membrane enzymes and kidney-associated cell surface antigens. The epithelial developmental antigen Exo-1 was expressed in 50% to 80% of cyst-lining epithelia in polycystic kidney tissue and in 20% to 30% of polycystic kidney cells cultured in vitro. Normal kidney cells and RCC were negative under identical culture conditions. The expression o…

medicine.medical_specialtyTGF alphaCellular differentiationAutosomal dominant polycystic kidney diseaseGene ExpressionBiologyKidneyEpitheliumProto-Oncogene Proteins c-mycGrowth factor receptorEpidermal growth factorInternal medicinemedicinePolycystic kidney diseaseHumansRNA MessengerGrowth SubstancesCarcinoma Renal CellCells CulturedKidneyurogenital systemAntibodies MonoclonalTransforming Growth Factor alphamedicine.diseasePolycystic Kidney Autosomal DominantAntigens DifferentiationImmunohistochemistryKidney NeoplasmsErbB ReceptorsEndocrinologymedicine.anatomical_structureGenesNephrologyAntigens SurfaceCancer researchTransforming growth factorAmerican journal of kidney diseases : the official journal of the National Kidney Foundation
researchProduct

Optimized culture conditions for tissue explants of uterine leiomyoma

2012

Background Uterine leiomyomas are the most common benign tumours in women, which arise from smooth muscle cells of the uterine myometrium and usually are multicentric. In spite of their frequency pathogenesis is widely unknown, mainly due to the absence of a suitable model system. We describe the systematic optimization of culturing leiomyoma tissue explants in an economical and effective ex vivo system. Methods Different concentrations of oxygen, different media, sera, hormones, and growth factor supplements were tested. Immunohistochemical stainings with antibodies against hormone receptors as well as specifying proliferation and apoptotic indices and real-time PCR were performed. Results…

medicine.medical_treatmentCulture Media; Epidermal Growth Factor; Estradiol; Female; Humans; Immunohistochemistry; Leiomyoma; Progesterone; RNA Messenger; Real-Time Polymerase Chain Reaction; Uterine NeoplasmsBiologyReal-Time Polymerase Chain ReactionGeneral Biochemistry Genetics and Molecular BiologyAndrologyTissue culturemedicineHumansRNA MessengerUterine NeoplasmProgesteroneUterine leiomyomaEpidermal Growth FactorEstradiolLeiomyomaGrowth factorMyometriummedicine.diseaseImmunohistochemistrySettore MED/40 - Ginecologia E OstetriciaCulture MediaLeiomyomaHormone receptorUterine NeoplasmsFemaleEx vivoHuman
researchProduct

Trastuzumab-emtansine induced pleural and pericardial effusions

2021

Introduction Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate which combine trastuzumab (T), a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), and a cytotoxic molecule derived from maytansine (DM1). Case report We report the first case of T-DM1-associated pleural and pericardial effusions three weeks after the second course of T-DM1 in a patient with breast cancer. Drug-induced pleural and pericardial effusions was implicated in the absence of other etiologies. The Naranjo Scale indicated a probable drug-induced adverse reaction. Management & outcome: The patient fully recovered after thoracentesis and discontinuation of T-DM1. The patient h…

musculoskeletal diseasesReceptor ErbB-2medicine.drug_classBreast NeoplasmsAdo-Trastuzumab EmtansineAntibodies Monoclonal HumanizedMonoclonal antibodyPericardial effusionPericardial Effusion03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTrastuzumabmedicineHumansMaytansinePharmacology (medical)business.industryHuman epidermal growth factorTrastuzumabmedicine.diseaseOncologychemistryTrastuzumab emtansine030220 oncology & carcinogenesisCancer researchFemalebusiness030215 immunologymedicine.drugConjugateJournal of Oncology Pharmacy Practice
researchProduct

Development of New Targeted Inulin Complex Nanoaggregates for siRNA Delivery in Antitumor Therapy.

2021

Here, a novel strategy of formulating efficient polymeric carriers based on the already described INU-IMI-DETA for gene material whose structural, functional, and biological properties can be modulated and improved was successfully investigated. In particular, two novel derivatives of INU-IMI-DETA graft copolymer were synthesized by chemical functionalisation with epidermal growth factor (EGF) or polyethylenglycol (PEG), named INU-IMI-DETA-EGF and INU-IMI-DETA-PEG, respectively, in order to improve the performance of already described “inulin complex nanoaggregates” (ICONs). The latter were thus prepared by appropriately mixing the two copolymers, by varying each component from 0 to 100 wt%…

siRNA deliveryRNase PCellPharmaceutical Science02 engineering and technology010402 general chemistry01 natural sciencesArticleAnalytical Chemistrylcsh:QD241-441EGF; inulin; PEG; siRNA delivery; targeting; tumourlcsh:Organic chemistryEpidermal growth factorNeoplasmsDrug DiscoveryPEG ratioZeta potentialmedicineCopolymerHumansDoxorubicinPhysical and Theoretical ChemistryRNA Small InterferingtargetingEGFDrug CarriersinulinChemistrytumourOrganic ChemistryTransfection021001 nanoscience & nanotechnologyPEG0104 chemical sciencesNanostructuresmedicine.anatomical_structureSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoChemistry (miscellaneous)BiophysicsMCF-7 CellsMolecular Medicine0210 nano-technologymedicine.drugMolecules (Basel, Switzerland)
researchProduct